# pleural mesothelioma stages

Types of lung cancer » There are 2 main groups of primary lung cancer, namely small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). The most common type is non small cell lung cancer. Cancerresearchuk.org

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 » In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. Annalsofoncology.org

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial » In patients with advanced pleural mesothelioma, the addition of pembrolizumab to standard platinum–pemetrexed chemotherapy was tolerable and resulted in a significant improvement in overall survival. This regimen is a new treatment option for previously untreated advanced pleural mesothelioma. Thelancet.com

Pleural Mesothelioma | Symptoms, Treatment, & Survival » Pleural mesothelioma develops in the lining of the lungs (pleura) 10-50 years after asbestos exposure. Get help for pleural mesothelioma now. Mesotheliomahope.com

Treatment by Cancer Type » Mesothelioma: Peritoneal. Version: 1.2024. Mesothelioma: Pleural. Version: 1.2024. Multiple Myeloma. Version: 3.2024. Myelodysplastic Syndromes. Version: 1.2024. Nccn.org

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study - PubMed » <span><i>Purpose:</i> Malignant pleural mesothelioma (MPM) is an aggressive cancer. Data are not available in prospective trials on correlations between genetic alterations and outcomes of therapies. In this study, we assessed the genetic profile of MPM patients (pts) in tissue samples. <i>Patients and Me</i></span> … Pubmed.ncbi.nlm.nih.gov

Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma | NEJM » New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individualize treatment strategies. We investigated whether fibulin-3 in plasma and pleural effusions could meet… Nejm.org